X0202 SCHEDULE 13G/A 0001425738 XXXXXXXX LIVE 3 Common Stock, par value $0.001 per share 03/31/2026 0001810182 ALX Oncology Holdings Inc. 00166B105 323 Allerton Avenue South San Francisco CA 94080 Rule 13d-1(c) Redmile Group, LLC DE 0.00 9214188.00 0.00 9214188.00 9214188.00 N 6.8 IA OO The information in Item 4 relating to the shares of the Issuer's common stock ("Common Stock") that are or may be deemed beneficially owned by Redmile Group, LLC ("Redmile") is incorporated herein by reference. Percentage based on: (i) 134,540,741 shares of Common Stock outstanding as of March 31, 2026, as reported by the Issuer in its Definitive Proxy Statement on Schedule 14A filed with the SEC on April 20, 2026 (the "Schedule 14A"); plus (ii) 1,250,000 shares of Common Stock issuable upon exercise of the Pre-Funded Warrants to purchase Common Stock (the "Warrants"). Jeremy C. Green X0 0.00 9214188.00 0.00 9214188.00 9214188.00 N 6.8 HC IN The information in Item 4 relating to the shares of Common Stock that are or may be deemed beneficially owned by Jeremy C. Green is incorporated herein by reference. Percentage based on: (i) 134,540,741 shares of Common Stock outstanding as of March 31, 2026, as reported by the Issuer in the Schedule 14A; plus (ii) 1,250,000 shares of Common Stock issuable upon exercise of the Warrants. Redmile Biopharma Investments III, L.P. DE 0.00 5267838.00 0.00 5267838.00 5267838.00 N 3.9 PN Redmile Biopharma Investments III, L.P. ("RBI III") may be deemed to beneficially own (i) 4,017,838 shares of Common Stock, and (ii) 1,250,000 shares of Common Stock issuable upon exercise of the Warrants directly held by RBI III. Percentage based on: (i) 134,540,741 shares of Common Stock outstanding as of March 31, 2026, as reported by the Issuer in the Schedule 14A; plus (ii) 1,250,000 shares of Common Stock issuable upon exercise of the Warrants directly held by RBI III. ALX Oncology Holdings Inc. 323 Allerton Avenue, South San Francisco, CA 94080 Redmile Group, LLC Jeremy C. Green Redmile Biopharma Investments III, L.P. Redmile Group, LLC 900 Larkspur Landing Circle, Suite 270 Larkspur, California 94939 Jeremy C. Green c/o Redmile Group, LLC (NY Office) 45 W. 27th Street, Floor 11 New York, NY 10001 Redmile Biopharma Investments III, L.P. c/o Redmile Group, LLC 900 Larkspur Landing Circle, Suite 270 Larkspur, California 94939 Redmile Group, LLC: Delaware Jeremy C. Green: United Kingdom Redmile Biopharma Investments III, L.P.: Delaware Y Redmile Group, LLC - 9,214,188 (1) Jeremy C. Green - 9,214,188 (1) Redmile Biopharma Investments III, L.P. - 5,267,838 (2) Redmile Group, LLC - 6.8% (3) Jeremy C. Green - 6.8% (3) Redmile Biopharma Investments III, L.P. - 3.9% (3) Redmile Group, LLC - 0 Jeremy C. Green - 0 Redmile Biopharma Investments III, L.P. - 0 Redmile Group, LLC - 9,214,188 (1) Jeremy C. Green - 9,214,188 (1) Redmile Biopharma Investments III, L.P. - 5,267,838 (2) Redmile Group, LLC - 0 Jeremy C. Green - 0 Redmile Biopharma Investments III, L.P. - 0 Redmile Group, LLC - 9,214,188 (1) Jeremy C. Green - 9,214,188 (1) Redmile Biopharma Investments III, L.P. - 5,267,838 (2) (1) As of March 31, 2026, Redmile's and Jeremy C. Green's beneficial ownership of Common Stock is comprised of (i) 7,964,188 shares of Common Stock and (ii) 1,250,000 shares of Common Stock issuable upon exercise of the Warrants. The Warrants are subject to a 9.99% beneficial ownership limitation. All of such shares of Common Stock and the Warrants are directly owned by certain investment vehicles, including RBI III, for which Redmile is the investment manager (the "Redmile Funds"). Redmile may be deemed to beneficially own these securities in its capacity as the investment manager with discretion to vote and dispose of all shares of Common Stock held by the Redmile Funds. Mr. Green also may be deemed to beneficially own these securities as the principal of Redmile. Redmile and Mr. Green each disclaim beneficial ownership of these securities, except to the extent of its or his pecuniary interest in such securities, if any. (2) RBI III may be deemed to beneficially own (i) 4,017,838 shares of Common Stock, and (ii) 1,250,000 shares of Common Stock issuable upon exercise of the Warrants directly held by RBI III. (3) Percentage based on: (i) 134,540,741 shares of Common Stock outstanding as of March 31, 2026, as reported by the Issuer in the Schedule 14A; plus (ii) 1,250,000 shares of Common Stock issuable upon exercise of the Warrants directly held by RBI III. N Y Y N See the response to Item 4. Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Redmile Group, LLC /s/ Jeremy C. Green 05/15/2026 Jeremy C. Green /s/ Jeremy C. Green 05/15/2026 Redmile Biopharma Investments III, L.P. /s/ Jeremy C. Green 05/15/2026